Related references
Note: Only part of the references are listed.Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities
Grace Lu-Yao et al.
EUROPEAN UROLOGY (2020)
Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model
Changhua Ji et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2020)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review
Zhen Liang et al.
ANDROLOGY (2020)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease
David Margel et al.
JOURNAL OF UROLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis
Xiaolei Zhu et al.
CANCER INVESTIGATION (2019)
Androgenic Effects on Ventricular Repolarization A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes
Joe-Elie Salem et al.
CIRCULATION (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
A population-based study of cardiovascular diseasemortality risk in US cancer patients
Kathleen M. Sturgeon et al.
EUROPEAN HEART JOURNAL (2019)
From trends to transformation: where cardio-oncology is to make a difference
Joerg Herrmann
EUROPEAN HEART JOURNAL (2019)
Role of Androgen Receptor in Prostate Cancer: A Review
Kazutoshi Fujita et al.
WORLD JOURNAL OF MENS HEALTH (2019)
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Kazuko Tajiri et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017
Graca M. Dores et al.
JAMA NETWORK OPEN (2019)
Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy
Ursula Kirchmayer et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2019)
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
Roberto Iacovelli et al.
CLINICAL GENITOURINARY CANCER (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis
Zhenlang Guo et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology
Jean-Pierre Droz et al.
EUROPEAN UROLOGY (2017)
Darolutamide (ODM-201) for the treatment of prostate cancer
Neal D. Shore
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications
Vasileios Tzortzis et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2017)
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA
Mario Eisenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
Raphael B. Moreira et al.
ONCOTARGET (2017)
Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi et al.
ESMO OPEN (2017)
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08
Justin C. Voog et al.
EUROPEAN UROLOGY (2016)
Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma
Teresa C. Longoria et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
Elena Verzoni et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Cecilia Bosco et al.
EUROPEAN UROLOGY (2015)
Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin
Ching-Hsia Hung et al.
TOXICOLOGICAL SCIENCES (2015)
Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events
Laurence Fardet et al.
DRUGS (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies
Jinsheng Zhao et al.
PLOS ONE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Androgen deprivation and thromboembolic events in men with prostate cancer
Behfar Ehdaie et al.
CANCER (2012)
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway
Adrian E. Campelo et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer
Mara M. Epstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The European Medicines Agency Review of Cabazitaxel (Jevtana®) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Pean et al.
ONCOLOGIST (2012)
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials
Paul L. Nguyen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association Endorsed by the American Society for Radiation Oncology
Glenn N. Levine et al.
CIRCULATION (2010)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden
Mieke Van Hemelrijck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
S. Barbar et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Jason E. Faris et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
Dose-related patterns of glucocorticoid-induced side effects
D. Huscher et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Shabbir M. H. Alibhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α1-adrenoceptor stimulation
S. Tsang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Re: Phase I Clinical Trial of a Selective inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Jack A. Schalken
EUROPEAN UROLOGY (2008)
Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02
Jason A. Efstathiou et al.
EUROPEAN UROLOGY (2008)
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610
Mack Roach et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Glucocorticoids and cardiovascular disease
Brian R. Walker
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
Henry K. Tsai et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Christopher S. Saigal et al.
CANCER (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis
Y Ikeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy
DC Beyer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Docetaxel for treatment of solid tumours: a systematic review of clinical data
A Montero et al.
LANCET ONCOLOGY (2005)
Sex and strain differences in adult mouse cardiac repolarization: importance of androgens
J Brouillette et al.
CARDIOVASCULAR RESEARCH (2005)
Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
A O'Donnell et al.
BRITISH JOURNAL OF CANCER (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Testosterone is a potent inhibitor of L-type Ca2+ channels
JL Scragg et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Studies on prostatic cancer - I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
C Huggins et al.
JOURNAL OF UROLOGY (2002)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Share Paper
